Presentations and videos

Presentations

Investor Presentation - February 2024

Date	Title	Presentation
06/02/2024	Investor Presentation - February 2024	1,654KB
26/10/2023	Interim Results for six months ended 31 July 2023	1,904KB
01/07/2023	Investor presentation: Is Drug Discovery a Data Science Problem?	2,654KB
04/05/2023	Final Results - Year End 31 January 2023	3,223KB
31/01/2022	Final Results - Year End 31 January 2022	15,810KB
01/10/2021	Interim results for six months ended 31 July 2021	5,263KB
01/05/2021	Investor presentation: Computational Drug Discovery - From Machine to Man	15,724KB

Date	06/02/2024
Title	Investor Presentation - February 2024
Presentation	1,654KB
Date	26/10/2023
Title	Interim Results for six months ended 31 July 2023
Presentation	1,904KB
Date	01/07/2023
Title	Investor presentation: Is Drug Discovery a Data Science Problem?
Presentation	2,654KB
Date	04/05/2023
Title	Final Results - Year End 31 January 2023
Presentation	3,223KB
Date	31/01/2022
Title	Final Results - Year End 31 January 2022
Presentation	15,810KB
Date	01/10/2021
Title	Interim results for six months ended 31 July 2021
Presentation	5,263KB
Date	01/05/2021
Title	Investor presentation: Computational Drug Discovery - From Machine to Man
Presentation	15,724KB

Videos and podcasts

Computing The Future of Medicine Investor Presentation (November 2023)

Ali Mortazavi presents on e-therapeutics' HepNet computational platform, including integration of LLMs, and GalOmic RNAi therapeutic pipeline at the LSX Investival Showcase (November 2023)

AI's Game-Changing Impact on Drug Discovery (July 2023)

Ali Mortazavi, presents on AI's game-changing impact on drug discovery, and how we are leveraging the recent LLM breakthroughs at e-therapeutics, in an Investor Presentation via Investor Meet Company (July 2023)

Beyond Biotech Podcast Interview discussing recent fundraising and therapeutic pipeline progress

e-therapeutics CEO Ali Mortazavi talks to Jim Cornall editor of Labtiotech.eu about recent Company momentum and executing a differentiated strategy using computation to understand biology better and identify novel drug targets.

Proactive Interview: OTCQX Launch of Trading and RNAi Platform Progress

e-therapeutics plc's CEO Ali Mortazavi joins Proactive London after the recent launch of trading on the OTCQX Best Market under the ticker symbol ETXPF.